NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland (ncpe.ie)

• NCPE completed HTA for belzutifan (Welireg) for VHL disease on 25 May 2026.
• Recommendation: not reimbursed unless cost-effectiveness improves.
• Assessment process spanned March 2025 to May 2026; full HTA commissioned by HSE.

"The National Centre for Pharmacoeconomics (NCPE) in Ireland has completed its health technology assessment of belzutifan (Welireg) for treating von Hippel-Lindau disease. The NCPE recommends that belzutifan not be reimbursed unless its cost-effectiveness improves relative to existing treatments. The assessment process ran from March 2025 to May 2026, culminating in a negative recommendation. The HSE will consider this report alongside patient submissions before making a final reimbursement decision under the Health (Pricing and Supply of Medical Goods) Act 2013."